VIRI News and Press, Virios Therapeutics Inc. From 06/04/21

Virios Therapeutics (VIRI) announces the dosing of the first patient in its Phase 2b clinical trial evaluating IMC-1 in patients with pain disorder fibromyalgia.Shares up more than 9% premarket.IMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir a...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today dosing of the first patient in its Phase 2b clinic...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that clinical data was highlighted in an oral pres...

Gainers: Onconova Therapeutics (ONTX) +44%.Park City (PCYG) +27%.Agenus (AGEN) +26%.Ultralife (ULBI) +23%.Virios Therapeutics (VIRI) +23%.Lordstown Motors (RIDE) +22%.Aemetis (AMTX) +22%.Aterian (ATER) +21%.Orbital Energy (OEG) +20%.BM Technologies (BMTX) +19%.Losers: Evofem Bioscie...

Virios Therapeutics, Inc. (VIRI) Q1 2021 Earnings Conference Call May 13, 2021 08:30 a.m. ET Company Representatives Greg Duncan - Chief Executive Officer Michael Gendreau - Chief Medical Officer Angela Walsh - Senior Vice President of Finance and Treasurer Ralph Grosswald - Vice President of...

Virios Therapeutics (VIRI): Q1 GAAP EPS of -$0.37.As of March 31, 2021, Virios Therapeutics cash totaled $24.6 million.Press Release For further details see: Virios Therapeutics reports Q1 results

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the first quarter ended March...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Off...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that its first quarter 2021 financial results will...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today announced an interview with Chairman and CEO, Greg Duncan, w...